Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

Annals of the Rheumatic Diseases

Volumn 68, Issue 2, 2009, Pages 216-221

  Keystone, E ^a,m   Emery, P ^b   Peterfy, C G ^c   Tak, P P ^d   Cohen, S ^e   Genovese, M C ^f   Dougados, M ^g   Burmester, G R ^h   Greenwald, M ⁱ   Kvien, T K ^j   Illiams, S ^k   Hagerty, D ^l   Cravets, M W ^l   Shaw, T ^k  

^a UNIVERSITY OF TORONTO   (Canada)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c SYNARC INC   (United States)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f STANFORD UNIVERSITY   (United States)

^g Hôpital Cochin ^*  (France)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ Desert Medical Advances   (United States)

^j DIAKONHJEMMET HOSPITAL   (Norway)

^k ROCHE PRODUCTS LTD   (United Kingdom)

^l BIOGEN   (United States)

^m MOUNT SINAI HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG INHIBITION; FEMALE; HUMAN; JOINT INJURY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58849088519     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.085787     Document Type: Article

References (21)

1. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984;27:864-72.
2. Corbett M, Dalton S, Young A, Silman A, Shipley M. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. Br J Rheumatol 1993;32:717-23.
3. Hulsmans HM, Jacobs JW, van der Heijde DM, van Albada-Kuipers GA, Schenk Y, Bijlsma JW. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000;43:1927-40.
4. Wolfe F, Sharp JT. Radiographic outcome of recent onset rheumatoid arthritis: a 19- year study of radiographic progression. Arthritis Rheum 1998;41:1571-82.
5. Scott DL Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000;39:122-32.
6. Paleolog E. The therapeutic potential of TNF-α blockade in rheumatoid arthritis. Expert Opin Investig Drugs 2003;12:1087-95.
7. Wolbink GJ, Vis M, Lems W, Voskuyl AE, De Groot E, Nurmohamed MT, et al. Development of anti-infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-15.
8. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
9. Edwards JC, Szczepariski L, Szechihski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
10. Cohen SB, Emery P, Greenwald M, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumour necrosis factor therapy. Arthritis Rheum 2006;54:2793-806.
11. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
13. Genant HK. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 1983;75:35-47.
14. Genant HK. lntetleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: radiologic progression and correlation of Genant/Sharp and Larsen scoring methods. Semin Arthritis Rheum 2001 ;30(Suppl 2):26-32.
15. Genant HK, Jiang Y, Peterfy C, Lu Y, Rédei J, Countryman P. Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998;41:1583-90.
16. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized and placebo controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scoring methods. Arthritis Rheum 2000;43:1001-9.
17. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:1-12.
18. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Birbara C, et al. Abatacept for rheumatoid arthritis refractory to tumour necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
19. Strand V, Sharp JT. Radiographic data from recent randomized controlled trials in rheumatoid arthritis: what have we learned? Arthritis Rheum 2003;48:21-34.
20. Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119-25.
21. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333:142-6.